James A. Mish

22nd Century Appoints Interim CEO, Implements $15M Cost Reduction Initiative
22nd Century To Secure $3M Via Registered Direct Offering Priced Above Market
22nd Century Group Q1 2023 Revenue Grows 142% YoY, What About Adjusted EBITDA?
22nd Century To Secure $3M Via Registered Direct Offering Priced Above Market
22nd Century Group Q1 2023 Revenue Grows 142% YoY, What About Adjusted EBITDA?
22nd Century Group Signs Exclusive License And Distribution Agreement With Cookies
22nd Century Group Q4 2022 Net Revenue Grows 141.3% YoY, What About Profit?

James A. Mish Recent News

22nd Century Group's GVB Biopharma Opens New Cannabis Distribution Facility In The Netherlands
GVB Biopharma, a 22nd Century Group company (NASDAQ: XXII) has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa.
22nd Century Group Q3 Revenue Grows 148% YoY, Here Are The Details
22nd Century Group, Inc. (NASDAQ: XXII) net revenues for the third quarter of 2022 were $19.4 million, an increase of 148.2% from 2021.
22nd Century Group Acquires Privately-Held Cannabis & Hemp Co., Here's What's Next
22nd Century Group, Inc. (NASDAQ: XXII) announced the acquisition of privately held GVB Biopharma. GVB - a contract development and manufacturing organization - provides hemp-derived active ingredients for the pharmaceutical and consumer goods industries worldwide.
22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows
22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET.
FDA-Authorized Reduced-Nicotine Cigarette From 22nd Century Group That 'Helps You Smoke Less' To Reach Illinois
22nd Century Group, Inc. (NASDAQ:XXII) received notification from the Office of the Illinois Attorney General's Tobacco Enforcement Bureau that its VLN cigarettes will be listed in the Illinois Directory of Participating Manufacturers effective April 4, 2022.
22nd Century Group And KeyGene Achieve Breakthrough In Hemp/Cannabis GMO Research
22nd Century Group, Inc.
22nd Century Group To Host Q4 & FY 2021 Earnings Call
22nd Century Group, Inc. (NASDAQ: XXII) announced that it will host a live webcast on Tuesday, March 1, 2022, at 10:00 AM ET to discuss its 2021 fourth quarter and full year results.
Aurora Cannabis, 22nd Century Group To License Biosynthesis Intellectual Property To Cronos
Canadian marijuana titan Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB) together with 22nd Century Group, Inc. (NASDAQ: XXII) will license biosynthesis intellectual property to Cro
Cannabis Movers & Shakers: Leafly, Origin Therapeutics, ECGI Holdings, 22nd Century Group
Leafly Hires Rebecca Warner As VP Of Sales The cannabis information platform Leafly Holdings, Inc. said Wednesday that it has hired Rebecca Warner to serve as senior vice president of sales.
22nd Century Group Reports Revenue Gains In Q3, Seeks To Monetize Its Hemp & Cannabis Plant Lines
Plant-based biotech company 22nd Century Group, Inc. (NASDAQ: XXII) reported its results on Thursday for the third quarter ended September 30, revealing net sales of $7.8 million for the period, up 6.9% from the prior year's period.
22nd Century Group Closes Registered Direct Offering, Raises $40M
Plant-based biotech company 22nd Century Group, Inc. (NYSE AMEX: XXII) has raised $40 million through a previously announced registered direct offering of its 10 million common shares at $4.00 per share. The Buffalo, New York-based company closed the offering on Wednesday.